Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ir-MT1
- Development stage
- Preclinical
- Lead developer
- Qilu Hospital of Shandong University
- Modality
- Small Molecules
- Administration
- Intratumoral
01
Overview
Ir-MT1 is a mitochondria-targeted iridium(III)-based photosensitizer developed for the photoimmunotherapy of renal cell carcinoma (RCC). Upon photoactivation with light, Ir-MT1 generates high levels of reactive oxygen species (ROS) within the mitochondria, leading to mitochondrial DNA leakage and calcium homeostasis disruption. This triggers a cascade of events including Caspase-1 cleavage and activation of the cGAS-STING and RIPK1-MLKL pathways, driving synergistic pyroptosis and necroptosis. This multi-pathway cell death promotes immunogenic cell death (ICD), enhancing dendritic cell activation, T-cell infiltration, and long-lasting antitumor immune memory to prevent tumor recurrence and metastasis.
Beyond the preview
Go deeper on Ir-MT1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ir-MT1.